Ultragenyx Data De-Risk Phase III Trial Of Setrusumab

 
• By Joseph Haas
Bone health
Ultragenyx's 14-month data for setrusumab shows sustained reduction of fractures • Source: Shutterstock

More from Clinical Trials

More from R&D